Zevra Therapeutics, Inc. (ZVRA) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Zevra Therapeutics, Inc. (ZVRA) stock forecast summary
Our AI ranks Zevra Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Zevra Therapeutics, Inc. is a small-cap company with a market capitalization of $617M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for ZVRA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ZVRA included.
Follow ZVRA freeZVRA price chart and AI forecast
How ZVRA ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Zevra Therapeutics, Inc. (ZVRA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | ZVRA | Rank |
|---|---|---|
| Market Cap | $617M | 60/60 |
| P/B Ratio | 2.83x | 39/43 |
| EPS | $0.28 | – |
| Book Value/Share | $3.67 | – |
| Revenue/Share | $2.29 | – |
| FCF/Share | $0.55 | – |
Profitability & Margins
| Metric | ZVRA | Rank |
|---|---|---|
| ROIC | 32.4% | 1/41 |
| Gross Margin | 94.5% | 4/29 |
| Operating Margin | 60.5% | 2/33 |
| EBT Margin | 50.9% | 5/40 |
| Tax Rate | 15.9% | – |
Financial Health
| Metric | ZVRA | Rank |
|---|---|---|
| Current Ratio | 5.17x | 17/50 |
| Quick Ratio | 5.12x | 5/37 |
| D/E Ratio | 0.39x | 28/43 |
| Financial Leverage | 1.39x | 28/43 |
| Interest Coverage | 12.2x | 11/36 |
| Working Capital | $203M | 46/50 |
Cash Flow
| Metric | ZVRA | Rank |
|---|---|---|
| Operating Cash Flow | $33M | 27/49 |
| Free Cash Flow | $33M | 23/39 |
| Capital Spending | -$780K | 6/39 |
| FCF/Sales | 24.0% | 11/34 |
| CapEx/Sales | 0.6% | 27/34 |
Operational Efficiency
| Metric | ZVRA | Rank |
|---|---|---|
| Asset Turnover | 0.45x | 19/38 |
| Inventory Turnover | 3.1x | 4/27 |
| Fixed Assets Turnover | 212.3x | 5/37 |
| Days Inventory | 119 days | 24/27 |
| Payables Period | 677 days | 2/23 |
Income Statement
| Metric | ZVRA | Rank |
|---|---|---|
| Total Revenue | $136M | 37/39 |
| Operating Income | $82M | 17/41 |
| R&D Expense | $15M | 48/48 |
| SG&A Expense | $75M | 35/35 |
| Cost of Goods Sold | $8M | 27/27 |
Dividend & Shareholder Information
| Metric | ZVRA | Rank |
|---|---|---|
| Shares Outstanding | 59M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $251M | 83.0% of assets |
| Cash & Short-term Investments | $145M | 48.0% of assets |
| Inventory | $2M | 0.8% of assets |
| Total Liabilities | $85M | 28.1% of assets |
| Short-term Debt | $35M | 11.5% of assets |
ZVRA quarterly financials and insider trading
Zevra Therapeutics, Inc. (ZVRA) industry peers
Companies classified under the same SEC industry code as Zevra Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ZVRA Zevra Therapeutics, Inc. | ▲ | $617M |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.83B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.73B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▼ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ABVX Abivax S.A. | ▼ | $6.77B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where ZVRA sits on the market map
Zevra Therapeutics, Inc. (ZVRA) stock news
Loading...
Zevra Therapeutics, Inc. (ZVRA) stock forecast FAQ
What is the Zevra Therapeutics, Inc. (ZVRA) stock forecast?
Our AI ranks Zevra Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Zevra Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for ZVRA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Zevra Therapeutics, Inc. forecasts updated?
Zevra Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Zevra Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, ZVRA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.